Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
교와기린은 로카틴리맙을 차별화된 혁신 치료 자산이자 높은 시장 잠재력을 지닌 ‘삶을 변화시키는 치료제’로 개발하겠다는 의지를 재확인병원성 T세포에 발현되는 OX40 수용체를 직접 표적으로 하는 T세포 균형 조절 치료제로서의 로카틴리맙의 새로운 접근법은 중등도에서 중증 아토피 피부염(msAD) 환자에서 장기적인 질환 조절 효과를 제공할 잠재력을 보여줘규제...
-
Kyowa Kirin bestätigt Engagement für die Entwicklung von Rocatinlimab als lebensveränderndes differenziertes Feld mit bedeutendem Marktpotenzial.Die neuartige Ausrichtung von Rocatinlimab als in der...
-
Kyowa Kirin reafirma su compromiso con el desarrollo de rocatinlimab como un activo diferenciado con potencial transformador y un potencial de mercado significativo.El enfoque innovador de...
-
Kyowa Kirin menegaskan komitmen syarikat terhadap pembangunan Rocatinlimab sebagai aset berbeza yang berpotensi mengubah kehidupan dengan prospek pasaran yang signifikan.Pendekatan inovatif...
-
Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential.Rocatinlimab’s novel approach as an investigational T-cell...
-
Princeton, NJ, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new clinical study data spotlighting the potential...
-
Princeton, NJ and TOKYO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET-SHUTTLE trial of rocatinlimab, an investigational...
-
THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced preliminary top-line results from the ASCEND study...
-
PRINCETON, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc. a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced the launch of a new tool to help healthcare providers (HCPs)...